Sean McClain

In this discussion, Sean McClain, Founder and CEO of AbSci, reveals his groundbreaking work in AI-driven drug design. He shares insights into the BS201 antibody for hair regrowth, explaining its unique ability to reactivate follicles while significantly lowering development costs. The conversation also touches on how AI is revolutionizing the identification of previously elusive targets in drug discovery, and the implications for regenerative medicine and longevity therapies. McClain envisions a future where AI replaces animal testing, transforming biotech.

Sean McClain, CEO of Absci, discusses using AI to speed up biologic drug discovery. Topics include the upcoming clinical testing of an antibody drug for inflammatory bowel disease in 2025, integrating AI into drug discovery, the creative aspects of biologic drug discovery, engineering E. coli for biologic therapies, evolving business models in biologic drug discovery, unexpected discoveries in drug compound affinity, and revolutionizing drug discovery with AI-generated biologics.

Sean McClain, CEO of Absci, and Andreas Busch, Chief Innovation Officer, discuss how AI is revolutionizing drug discovery. They delve into tackling 'undruggable' targets, emphasizing how AI reduces development timelines and costs. Sean shares Absci's shift to biologics and the importance of partnerships with Big Pharma like AstraZeneca. Andreas reflects on his transition from Big Pharma to biotech, highlighting innovation in smaller companies. Together, they explore the future of drug development in an increasingly AI-driven landscape.

Sean McClain, Founder and CEO of AbSci, discusses using AI for drug development, the fusion of engineering and biology, the power of mentors in entrepreneurship, fostering diverse perspectives in leadership teams, and the challenges of pivoting to generative AI for antibodies.

Sean McClain, Founder and CEO of Absci, and Joshua Meier, Lead AI Scientist at Absci, share insights on how AI is revolutionizing drug discovery. They discuss the transition from traditional methods to AI-driven techniques, emphasizing the potential of digital twins and mRNA technology. The duo explores how AI analyzes biological data for personalized medicine and enhances clinical trials. With promises of more efficient drug development, their vision showcases a future where AI solutions lead to innovative healthcare transformations.